MLTX logo

MoonLake Immunotherapeutics (MLTX)

$17.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MLTX

Market cap

$1.29B

EPS

-3.88

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.056717

Price on MLTX

Previous close

$17.93

Today's open

$17.94

Day's range

$17.45 - $18.11

52 week range

$5.95 - $62.75

Profile about MLTX

CEO

Jorge Santos da Silva

Employees

100

Headquarters

Zug,

Exchange

NASDAQ Capital Market

Shares outstanding

73615396

Issue type

Common Stock

MLTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MLTX

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Jul 31, 2026

news preview

MoonLake Immunotherapeutics' CFO Sells 39K Shares

The executive sold 39,120 shares on June 22. The sale represented 3.4% of Bodenstedt's direct holdings.

news source

The Motley Fool • Jul 3, 2026

news preview

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion

MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for sonelokimab in HS by end of September 2026, targeting both adults and adolescents, with possible acceptance for review by November 2026. 52-week VELA data show 67.2% HiSCR75 response, positioning sonelokimab as a potential best-in-class therapy and supporting a broad label proposal thanks to VELA-TEEN adolescent study.

news source

Seeking Alpha • Jun 26, 2026

news preview

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.

news source

The Motley Fool • Jun 24, 2026

news preview

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares at a public offering price per pre-funded warrant of $19.9999, which equals the public offering price per Class A ordinary share less the $0.0001 per share exercise price of each pre-funded warrant. The pre-funded warrants are exercisable immediately. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be approximately $200 million. In addition, MoonLake has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,500,000 Class A ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 25, 2026 subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.

news source

GlobeNewsWire • Jun 24, 2026

news preview

MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher

MoonLake Immunotherapeutics is positioned for upside on differentiated efficacy and a large, underpenetrated hidradenitis suppurativa, or HS, market. Recent Phase 3 VELA data show sonelokimab achieves superior HiSCR75/100 response rates and meaningful patient-reported quality of life improvements. The commercial strategy targets a best-in-class FDA label by emphasizing efficacy, safety, and patient outcomes, supporting share gains in a $10–15B market.

news source

Seeking Alpha • Jun 23, 2026

news preview

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

news source

Seeking Alpha • Jun 22, 2026

news preview

MoonLake Immunotherapeutics Announces Proposed Public Offering

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, MoonLake is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $22.5 million of its Class A ordinary shares offered in the proposed offering at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by MoonLake.

news source

GlobeNewsWire • Jun 22, 2026

news preview

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the Week 52 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS. The Company also announced that it will host an Investor Day webcast on June 22, 2026, 8:00 – 9:30 a.m. EST (2:00 – 3:30 p.m. CET), including an open Q&A session.

news source

GlobeNewsWire • Jun 21, 2026

news preview

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?

Bodenstedt sold 13,653 shares for a transaction value of ~$273,000 at around $20.02 per share on May 11, 2026. The sale represented 1.1% of his direct holdings, reducing his direct position from 1,186,084 to 1,172,431 shares.

news source

The Motley Fool • Jun 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MoonLake Immunotherapeutics

Open an M1 investment account to buy and sell MoonLake Immunotherapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MLTX on M1